Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES AND LONG-TERM LIABILITIES (Tables)

v3.21.2
ACCRUED EXPENSES AND LONG-TERM LIABILITIES (Tables)
 9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
SCHEDULE OF OTHER ACCRUED EXPENSES

Other accrued expenses consisted of the following as of September 30, 2021 and December 31, 2020:

 

    September 30, 2021     December 31, 2020  
    (unaudited)        
Accrued royalties   $ 3,572     $ 2,710  
Upfront Medicare payment     -       2,066  
Operating lease liabilities     1,030       1,027  
All others     1,056       1,182  
Accrued professional fees     931       854  
Unclaimed property     565       565  
Contingent consideration     473       398  
Accrued pharma services invoices     438       108  
Taxes payable     248       334  
Accrued lab costs - diagnostics     514       161  
Financing lease liabilities     98       177  
ESPP payable     37       108  
Accrued sales and marketing - diagnostics     41       51  
Deferred revenue     40       54  
Total other accrued expenses   $ 9,043     $ 9,795  
SCHEDULE OF LONG TERM LIABILITIES

Long-term liabilities consisted of the following as of September 30, 2021 and December 31, 2020:

 

    September 30, 2021     December 31, 2020  
    (unaudited)        
Uncertain tax positions   $ 4,517     $ 4,342  
Warrant liability     158       21  
Financing lease liabilities     75       138  
Deferred revenue     18       136  
Total other long-term liabilities   $ 4,768     $ 4,637